Fig. 2From: Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature reviewSummary of the Cochrane risk of bias assessment in included RCTs (A) overall and (B) in individual studies. Domain 1, randomisation process; domain 2, deviations from the intended interventions; domain 3, missing outcome data; domain 4, measurement of the outcome; domain 5, selection of the reported result. RCT, randomised controlled trialBack to article page